Esophageal Squamous Cell Carcinoma
Medicine & Life Sciences
100%
Neoplasms
Medicine & Life Sciences
35%
Barrett Esophagus
Medicine & Life Sciences
35%
Chemoradiotherapy
Medicine & Life Sciences
33%
Tumor Microenvironment
Medicine & Life Sciences
26%
Adenocarcinoma
Medicine & Life Sciences
24%
Esophagus
Medicine & Life Sciences
22%
Carcinoma
Medicine & Life Sciences
22%
Okamoto, H. ,
Taniyam, Y. ,
Sato, C. ,
Fukutomi, T. ,
Ozawa, Y. ,
Ando, R. ,
Takahashi, K. ,
Akaishi, R. ,
Horie, Y. ,
Shinozaki, Y. ,
Unno, M. &
Kamei, T. ,
2022 ,
In: Asian Pacific Journal of Cancer Prevention. 23 ,
2 ,
p. 495-499 5 p. 研究成果: Article › 査読
Docetaxel
100%
Chemoradiotherapy
95%
Esophageal Neoplasms
91%
Fluorouracil
85%
Uterine Cervical Neoplasms
82%
Ito, K. ,
Ishida, H. ,
Fujishima, F. ,
Nakamura, Y. ,
Konno, T. ,
Ise, K. ,
Hata, S. ,
Ozawa, Y. ,
Taniyama, Y. ,
Kamei, T. &
Sasano, H. ,
2022 6月 ,
In: Anticancer research. 42 ,
6 ,
p. 2875-2882 8 p. 研究成果: Article › 査読
nutlin 3
100%
Esophageal Squamous Cell Carcinoma
73%
Esophageal Neoplasms
25%
Cisplatin
22%
Cell Line
14%
Tsunokake, J. ,
Fujishima, F. ,
Watanabe, H. ,
Sato, I. ,
Miura, K. ,
Sakamoto, K. ,
Suzuki, H. ,
Sawai, T. ,
Itakura, Y. ,
Hoshi, T. ,
Kunimitsu, A. ,
Yamauchi, T. ,
Akaishi, R. ,
Ozawa, Y. ,
Fukutomi, T. ,
Okamoto, H. ,
Sato, C. ,
Taniyama, Y. ,
Kamei, T. &
Sasano, H. ,
2022 5月 1 ,
In: Cancers. 14 ,
9 , 2152.
研究成果: Article › 査読
Tumor Microenvironment
100%
Neoplasms
31%
Ozawa, Y. ,
Hicks, K. C. ,
Minnar, C. M. ,
Knudson, K. M. ,
Schlom, J. &
Gameiro, S. R. ,
2021 ,
In: OncoImmunology. 10 ,
1 , 1915561.
研究成果: Article › 査読
Tumor Microenvironment
100%
Myeloid-Derived Suppressor Cells
85%
Monoclonal Antibodies
70%
Clinical Studies
44%
Blocking Antibodies
38%
Gatti-Mays, M. E. ,
Gameiro, S. R. ,
Ozawa, Y. ,
Knudson, K. M. ,
Hicks, K. C. ,
Palena, C. ,
Cordes, L. M. ,
Steinberg, S. M. ,
Francis, D. ,
Karzai, F. ,
Lipkowitz, S. ,
Donahue, R. N. ,
Jochems, C. ,
Schlom, J. &
Gulley, J. L. ,
2021 3月 5 ,
In: Frontiers in Oncology. 10 , 581801.
研究成果: Article › 査読
Brachyury protein
100%
Histone Deacetylase Inhibitors
75%
entinostat
70%
Immunotherapy
56%
Vaccines
48%